Granted Patent
B2
US 12,234,476 · App. 16/076,946 · Granted Feb 25, 2025
VCN enhancer compositions and methods of using the same
Assignee:
BLUEBIRD BIO, INC.
C12N15/867C12N5/0647C12N7/00C12N2501/02C12N2501/999C12N2510/00C12N2740/15011C12N2740/15041C12N2740/16011C12N2740/16041C12N2740/16043
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention provides improved gene therapy methods and compositions.
Claims (29)
1. A method of increasing the vector copy number (VCN) in a population of CD34+ hematopoietic stem or progenitor cells comprising culturing the cells for at least two hours in the presence of: (1) a lentiviral vector at a multiplicity of infection (MOI) of about 10 to about 30; (2) a prostaglandin E 2 (PGE 2 ), or 16,16-dimethyl PGE 2 ; and (3) poloxamer 338, wherein the increase of VCN achieved by culturing the cells for at least two hours in the presence of the lentiviral vector, poloxamer 338 and one of PGE 2 or 16,16-dimethyl PGE 2 is further enhanced beyond the increased VCN achieved by culturing the cells for at least two hours in the presence of the lentiviral vector and one of PGE 2 or 16,16-dimethyl PGE 2 and the absence of poloxamer 338.
2. The method of claim 1 , wherein the hematopoietic stem or progenitor cells are selected for CD34 + expression prior to transduction.
3. The method of claim 1 , wherein the CD34+ hematopoietic stem or progenitor cells comprise the B-globin alleles selected from the group consisting of: β E /β 0 , β C /β 0 , β 0 /β 0 , β E /β E , β C /β + , β E /β + , β 0 /β + , β + /β + , β C /β C , β E /β S , β 0 /β S , β C /β S , β + /β S and β S /β S .
4. The method of claim 1 , wherein the CD34+ hematopoietic stem or progenitor cells comprise the B-globin alleles selected from the group consisting of: β E /β 0 , β 0 /β 0 , β E /β E , β E /β + , β 0 /β + , and β + /β + .
5. The method of claim 1 , wherein the lentiviral vector is cultured with the cells at an MOI of about 10 to about 25, or about 10 to about 20.
6. The method of claim 1 , wherein the lentiviral vector is cultured with the cells at an MOI of about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29 or about 30.
7. The method of claim 1 , wherein the lentiviral vector is derived from an HIV-1 lentivirus.
8. The method of claim 1 , wherein the lentiviral vector comprises:
a) a 5′ long terminal (LTR);
b) a Psi (Ψ) packaging signal;
c) an RNA export element;
d) a lentiviral central polypurine tract (cPPT);
e) a promoter operably linked to a polynucleotide of interest; and
f) a SIN 3′ LTR.
9. The method of claim 1 , wherein the lentiviral vector comprises:
a) a 5′ long terminal (LTR) comprising a cytomegalovirus (CMV) promoter;
b) a Psi (Ψ) packaging signal;
c) a Rev response element (RRE);
d) a lentiviral central polypurine tract (cPPT);
e) a human β-globin LCR and human β-globin promoter operably linked to a polynucleotide encoding a globin; and
f) a self-inactivating (SIN) 3′ LTR that comprises a synthetic polyadenylation sequence.
10. The method of claim 9 , wherein the globin is selected from the group consisting of: a human β-globin, a human δ-globin, a human γ-globin, a human β A-T87Q -globin, a human β A-G16D/E22A/T87Q -globin, and a human β A-T87Q/K95E/K120E -globin.
11. The method of claim 1 , wherein the lentiviral vector is an AnkT9W vector, a T9Ank2W vector, a TNS9 vector, a lentiglobin HPV569 vector, a lentiglobin BB305 vector, a BG-1 vector, a BGM-1 vector, a d432BAγ vector, a mLARβΔγV5 vector, a GLOBE vector, a G-GLOBE vector, a βAS3-FB vector, a V5 vector, a V5m3 vector, a V5m3-400 vector, a G9 vector, or a BCL11A shmir vector.
12. The method of claim 1 , wherein the cells are cultured in the presence of PGE 2 .
13. The method of claim 1 , wherein the cells are cultured in the presence of 16,16-dimethyl PGE 2 .
14. The method of claim 1 , wherein the PGE 2 or 16,16-dimethyl PGE 2 is present in the culture in a concentration of about 10 μM to about 100 μM.
15. The method of claim 14 , wherein the PGE 2 or 16,16-dimethyl PGE 2 is present in the culture in a concentration of about 10 μM to about 50 μM.
16. The method of claim 1 , wherein the poloxamer 338 is present in the culture in a concentration of about 50 μg/mL to about 1000 μg/mL.
17. The method of claim 16 , wherein the poloxamer 338 is present in the culture in a concentration of about 62.5 μg/mL to less than 1000 μg/mL.
Assignments (3)
CHANGE OF NAME
Recorded Sep 25, 2025
From: BLUEBIRD BIO, INC.
To: GENETIX BIOTHERAPEUTICS INC.
Reel/Frame 072955/0154 →
SECURITY INTEREST
Recorded Mar 15, 2024
From: BLUEBIRD BIO, INC.
To: HERCULES CAPITAL, INC., AS AGENT
Reel/Frame 066801/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 19, 2018
From: BONNER, MELISSA; NEGRE, OLIVIER
To: BLUEBIRD BIO, INC.
Reel/Frame 047237/0817 →
Continuity (5)
Provisional Application
62294615
· Feb 12, 2016
Provisional Application
62313571
· Mar 25, 2016
Provisional Application
62417085
· Nov 3, 2016
Provisional Application
62429514
· Dec 2, 2016
References Cited (294)
US 4873192A
· Kunkel et al.
· 1989
[cited by applicant]
US 5460964A
· Mcglave et al.
· 1995
[cited by applicant]
US 5635387A
· Fei et al.
· 1997
[cited by applicant]
US 5677136A
· Simmons et al.
· 1997
[cited by applicant]
US 5716827A
· Tsukamoto et al.
· 1998
[cited by applicant]
US 5750397A
· Tsukamoto et al.
· 1998
[cited by applicant]
US 5759793A
· Schwartz et al.
· 1998
[cited by applicant]
US 5861488A
· Leboulch et al.
· 1999
[cited by applicant]
US 5864029A
· Townes et al.
· 1999
[cited by applicant]
US 5869039A
· Mandel et al.
· 1999
[cited by applicant]
US 5877288A
· Townes et al.
· 1999
[cited by applicant]
US 5994136A
· Naldini et al.
· 1999
[cited by applicant]
US 6013516A
· Verma et al.
· 2000
[cited by applicant]
US 6013769A
· Mandel et al.
· 2000
[cited by applicant]
US 6051402A
· Leboulch et al.
· 2000
[cited by applicant]
US 6057117A
· Harrison et al.
· 2000
[cited by applicant]
US 6608063B2
· Nuss et al.
· 2003
[cited by applicant]
US 6610719B2
· Paralkar et al.
· 2003
[cited by applicant]
US 6649595B2
· Clackson et al.
· 2003
[cited by applicant]
US 6670323B1
· Looker et al.
· 2003
[cited by applicant]
US 6682907B1
· Charneau et al.
· 2004
[cited by applicant]
US 6747037B1
· Old et al.
· 2004
[cited by applicant]
US 6822112B1
· Sato et al.
· 2004
[cited by applicant]
US 7901671B2
· Leboulch et al.
· 2011
[cited by applicant]
US 8029780B2
· Kollet et al.
· 2011
[cited by applicant]
US 8241903B2
· Lapidot et al.
· 2012
[cited by applicant]
US 8367057B2
· Lapidot et al.
· 2013
[cited by applicant]
US 8858928B2
· Denaro et al.
· 2014
[cited by applicant]
US 9061031B2
· Denaro et al.
· 2015
[cited by applicant]
US 9068199B2
· Leboulch et al.
· 2015
[cited by applicant]
US 9107909B2
· Pelus et al.
· 2015
[cited by applicant]
US 9675641B2
· Pelus et al.
· 2017
[cited by applicant]
US 9771599B2
· Anastasov et al.
· 2017
[cited by applicant]
US 9988644B2
· Heffner et al.
· 2018
[cited by applicant]
US 20030166631A1
· Dumont et al.
· 2003
[cited by applicant]
US 20050079616A1
· Reubinoff et al.
· 2005
[cited by applicant]
US 20050163760A1
· Cartier-Lacave et al.
· 2005
[cited by applicant]
US 20060247214A1
· DeLong et al.
· 2006
[cited by applicant]
US 20070087988A1
· Sawasdikosol et al.
· 2007
[cited by applicant]
US 20080021078A1
· Tidmarsh et al.
· 2008
[cited by applicant]
US 20100183519A1
· Katz et al.
· 2010
[cited by applicant]
US 20100184032A1
· Georgantas et al.
· 2010
[cited by applicant]
US 20100248254A1
· Perreault et al.
· 2010
[cited by applicant]
US 20110224227A1
· Sharpless et al.
· 2011
[cited by applicant]
US 20140255363A1
· Metelitsa et al.
· 2014
[cited by applicant]
US 20150216903A1
· Heffner et al.
· 2015
[cited by applicant]
US 20190365814A1
· Diaconu et al.
· 2019
[cited by applicant]
US 20240229070A1
· Heffner et al.
· 2024
[cited by applicant]
AU 2017217813A1
· 2018
[cited by applicant]
EP 3414321A1
· 2018
[cited by applicant]
FR 3074189A1
· 2017
[cited by applicant]
RU 2280074C2
· 2006
[cited by applicant]
WO WO1992011355A1
· 1992
[cited by applicant]
WO WO1998000541A2
· 1998
[cited by applicant]
WO WO2000023567A2
· 2000
[cited by applicant]
WO WO2000038663A2
· 2000
[cited by applicant]
WO WO2001012596A1
· 2001
[cited by applicant]
WO WO2002088346A2
· 2002
[cited by applicant]
WO WO2004098531A2
· 2004
[cited by applicant]
WO WO2006047476A2
· 2006
[cited by applicant]
WO WO2007071456A1
· 2007
[cited by applicant]
WO WO2007112084A2
· 2007
[cited by applicant]
WO WO2008070310A2
· 2008
[cited by applicant]
WO WO2008073748A1
· 2008
[cited by applicant]
WO WO2010054271A1
· 2010
[cited by applicant]
WO WO2010108028A2
· 2010
[cited by applicant]
WO WO2013049615
· 2013
[cited by applicant]
WO WO2013127964A1
· 2013
[cited by applicant]
WO WO2014026110A2
· 2014
[cited by examiner]
WO WO2015017214A1
· 2015
[cited by applicant]
WO WO2015059674A1
· 2015
[cited by applicant]
WO WO2015104376A1
· 2015
[cited by applicant]
WO WO2015162594A2
· 2015
[cited by applicant]
WO WO2016014794A1
· 2016
[cited by applicant]
WO WO2016201394A1
· 2016
[cited by applicant]
WO WO2017139561A1
· 2017
[cited by applicant]
WO WO2018148502A1
· 2018
[cited by applicant]
Finotti et al. Journal of Blood Medicine 2015:6. pp. 69-85 (Year: 2015).
[cited by examiner]
Extended European Search Report issued in European Application No. 18751122.5 dated Oct. 16, 2020, 6 pages.
[cited by applicant]
Kaur et al., “Addressing the challenge: current and future directions in ovarian cancer therapy,” Curr Gene Ther. Dec. 2009;9(6):434-58.
[cited by applicant]
Kotterman et al., “Engineering adeno-associated viruses for clinical gene therapy,” Nat Rev Genet. Jul. 2014;15(7):445-51.
[cited by applicant]
Lenzi et al., 2014, NCBI Bookshelf, A Service of the National Library of Medicine, National Institute of Health, Oversight and Review of Clinical Gene Transfer Protocols: Assessing the Role of the Recombinant DNA Adviso…
[cited by applicant]
Denning et al., “Optimization of the Transductional Efficiency of Lentiviral Vectors: Effect of Sera and Polycations”, Mol Biotechnol (2013), 53: 308-314.
[cited by applicant]
Blomer et al., “Highly Efficient and Sustained Gene Tranfer in Adult Neurons with a Lentivirus Vector,” 1997, Journal of Virology, vol. 71, No. 9, p. 6641-6649.
[cited by applicant]
Ikeda et al., “Gene transduction efficiency in cells of different species by HIV and EIAV vectors”, Gene Therapy (2002), 9: 932-938.
[cited by applicant]
Allegrucci et al., “Differences between human embryonic stem cell lines”, Human Reproduction Update (2006), pp. 1-18; Advance Access published on Aug. 26, 2006.
[cited by applicant]
Kolf et al., “Mesenchymal stromal cells. Biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation”, Arthritis Research & Therapy (2007), 9: 204, 10 pages.
[cited by applicant]
Hematti et al., “Retroviral transduction efficiency of G-CSF+SCF-mobilized peripheral blood CD34+ cells is superior to G-CSF or G-CSF+Flt3-L-mobilized cells in nonhuman primates”, Blood (2003), 101(6): 2199-2205.
[cited by applicant]
Akkina et al., “High-Efficiency Gene Transfer into CD341 Cells with a Human Immunodeficiency Virus Type 1-Based Retroviral Vector Pseudotyped with Vesicular Stomatitis Virus Envelope Glycoprotein G”, Journal of Virology…
[cited by applicant]
International Preliminary Report on Patentability and Written Opinion of the International Searching Authority issued by the Korean Intellectual Property Office for corresponding International Application No. PCT/US2012…
[cited by applicant]
International Search Report issued by the Korean Intellectual Property Office for corresponding International Application No. PCT/US2012/057987, dated Dec. 14, 2012, five pages.
[cited by applicant]
Goessling et al., “Prostaglandin E2 Enhances Human Cord Blood Stem Cell Xenotransplants and Shows Long-Term Safety in Preclinical Nonhuman Primate Transplant Models,” Cell Stem Cell (2011), 8: 445-458.
[cited by applicant]
Pelus et al., “Pleiotropic Effects of Prostaglandin E2 in Hematopoiesis: Prostaglandin E2 and Other Eicosanoids Regulate Hematopoietic Stem and Progenitor Cell Function,” Prostaglandins & Other Lipid Mediators 96:3-9 (J…
[cited by applicant]
Supplementary European Search Report for European Patent Application No. EP 12836507, dated Jan. 23, 2015.
[cited by applicant]
Mostoslaysky, et al., “Efficiency of Transduction of Highly Purified Murine Hematopoietic Stem Cells by Lentiviral and Oncoretoviral Vectors Under Conditions of Minimal in Vitro Manipulation”, Molecular Therapy, 11(6): …
[cited by applicant]
Puthenveetil, Geetha, et al. “Successful correction of the human β-thalassemia major phenotype using a lentiviral vector.” Blood 104.12 (2004): 3445-3453.
[cited by applicant]
Chen, Wen Yong, et al. “Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase.” Proceedings of the National Academy of Sciences 94.11 (1997): 5798-5803.
[cited by applicant]
Tobias, Chris A. et al. “Improved recombinant retrovirai titers utilizing trichostatin A.” Biotechniques 29:4 (2000): 884-891.
[cited by applicant]
Sugimoto, “Signaling crosstalk regulates prostanoid actions in physiology and pathology,” Experimental Medicine, 2009, vol. 27, No. 13, pp. 2047-2052.
[cited by applicant]
Miyoshi, “Transduction of hematopoietic stem cells by lentiviral vectors,” Virus, 2002, vol. 52, No. 2, pp. 225-231, abtract translation only.
[cited by applicant]
Abeyta, Michael J., et al. “Unique gene expression signatures of independently-derived human embryonic stem cell lines.” Human molecular genetics13.6 (2004):601-608.
[cited by applicant]
Alenzi, Fads Q.B., and Ali H. Bahkali. “Stem cells: Biology and clinical potential.” African Journal of Biotechnology10.86 (2011):19929-19940.
[cited by applicant]
Bank, Arthur. “Hematopoietic stem cell gene therapy: selecting only the best,” Journal of Clinical Investigation 112.10 (2003):1478.
[cited by applicant]
Chattopadhyay, Anasuyam Tamal Raha, and M. S. Shaila. “Effect of single amino acid mutations in the conserved GDNQ motif of L protein of Rinderpest virus on RNA synthesis in vitro and in vivo”. Virus research 99.2 (2004…
[cited by applicant]
Dupuis, Fabienne, et al. “Prostaglandin E 2 Stimulates the Growth of Human Blood CD34 Progenitors.” Prostaglandins & other lipid mediators 55.2 (1998):179-186.
[cited by applicant]
Feher, I. et al., “Prostaglandin E2 as stimulator of haemopoietic stem cell proliferation.” Nature 247.5442 (1974):550-551, Abstract.
[cited by applicant]
Goichberg, Polina, et al. “CAMP-induced PKCζ activation increases functional CXCR4 expression on human CD34+ hematopoietic progenitors.” Blood107.3 (2006):870-879.
[cited by applicant]
Hoggatt, Jonathan, et al. “Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation.” Blood 113.22 (2009):5444-5455.
[cited by applicant]
Horn, Peter A., et al. “Stem cell gene transfer-efficacy and safety in large animal studies.” Molecular Therapy 10.3 (2004):417-431.
[cited by applicant]
Levesque, Jean-Pierre et al., “Mobilization of hematopoietic stem cells: state of the art.” Current opinion in organ transplantation 13.1 (2003):53-58.
[cited by applicant]
Li, Shengqiao, Mark Waer, and An D. Billiau. “Xenotransplantation: role of natural immunity.” Transplant immunology 21.2 (2009):70-74.
[cited by applicant]
Lord, Allegra M., Trista E. North, and Leonard I. Zon. “Prostaglandin E2: making more of your marrow.” Cell Cycle 6.24 (2007):3054-3057.
[cited by applicant]
McGiff, John C. “Prostaglandins, prostacyclins, and thromboxanes.” Annual review of pharmacology and toxicology 21.1 (1981):479-509.
[cited by applicant]
North, Trista E., et al. “Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis.” Nature 447.7147 (2007):1007-1011.
[cited by applicant]
Sato, Noboru, et al. “Molecular signature of human embryonic stem cells and its comparison with the mouse.” Developmental biology 260.2 (2003):404-413.
[cited by applicant]
Skolnick, Jeffrey, and Jacquelyn S. Fetrow. “From genes to protein structure and function: novel applications of computational approaches in the genomic era.” Trends in biotechnology 18.1 (2000):34-39.
[cited by applicant]
Smallwood, Sherin, et al. “Different substitutions at conserved amino acids in domains II and III in the Sendai L RNA polymerase protein inactivate viral RNA synthesis.” Virology 304.1 (2002):135-145.
[cited by applicant]
Sprangers, Ben, Waer, Mark, and Billiau, A. D. “Xenotransplantation: where are we it 2008?” Kidney international 74.1 (2008):14-21.
[cited by applicant]
Taha, Masoumeh F. “Cell based-gene delivery approaches for the treatment of spinal cord injury and neurodegenerative disorders.” Current stein cell research & therapy 5.1 (2010):23-36.
[cited by applicant]
Tomasinsig, L., and M. Zanetti. “The cathelicidins-structure, function and evolution.” Current Protein and Peptide Science 6.1 (2005):23-34.
[cited by applicant]
Whitehurst, Christopher B., et al. “Single and multiple deletions in the transmembrane domain of the Sindbis virus E2 glycoprotein identify a region critical for normal virus growth.” Virology 347.1 (2006):199-207.
[cited by applicant]
Zhao, Wenxiu, et al. “Embryonic stem cell markers.” Molecules 17.6 (2012):6196-6236.
[cited by applicant]
Evers, Raymond, et al. “Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1.” FEBS letters 419.1 (1997):112-116.
[cited by applicant]
Paumi, Christian M., et al. “Multidrug resistance protein (MRP) 1 and MRP3 attenuate cytotoxic and transactivating effects of the cyclopentenone prostaglandin, 15-deoxy-A12, 14prostaglandin J2 in MCF7 breast cancer cell…
[cited by applicant]
Sutton, Richard E., et al. “Transduction of human progenitor hematopoietic stem cells by human immunodeficiency virus type 1-based vectors is cell cycle dependent.” Journal of Virology 73.5 (1999):3649-3660.
[cited by applicant]
Sugimoto, Yukihiko et al., “Prostaglandin E receptors.” Journal of Biological Chemistry 282.16 (2007):11613-11617.
[cited by applicant]
Buczynski, M. W. et al., “An integrated omics analysis of eicosanoid biology” Journal of Lipid Research 50.7 (2009):1015-1038.
[cited by applicant]
Follenzi, Antonia, et al. “Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences.” Nature Genetics 25.2 (2000):217-222.
[cited by applicant]
Demaison, Christophe, et al. “High-level transduction and gene expression in hematopoietic repopulating cells using a human imunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus formin…
[cited by applicant]
Notice of opposition to a European Patent in Patent No. EP2760994, on behalf of Muller Fottner Steinecke, dated Feb. 27, 2018.
[cited by applicant]
Notice of opposition to a European Patent in Patent No. EP2760994, on behalf of Sagittarius Intellectual Property LLP, dated Feb. 28, 2018.
[cited by applicant]
Paszkiet, BJ, et al., “Histone Deacetylation Inhibitors Enhance Lentiviral Vector Production and Infectivity,” Molecular Therapy, vol. 5, special issue 5, S308, May 1, 2002.
[cited by applicant]
Non-Final Office Action issued in U.S. Appl. No. 14/348,572, dated Nov. 6, 2015.
[cited by applicant]
Final Office Action issued in U.S. Appl. No. 14/348,572, dated Apr. 26, 2016.
[cited by applicant]
Non-Final Office Action issued in U.S. Appl. No. 14/348,572, dated Mar. 28, 2017.
[cited by applicant]
Notice of Allowance and Fees Due issued in U.S. Appl. No. 14/348,572, dated Aug. 15, 2017.
[cited by applicant]
Notice of Allowance and Fees Due issued in U.S. Appl. No. 14/348,572, dated Feb. 5, 2018.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2018/017557, dated Jun. 14, 2018, 11 pages.
[cited by applicant]
Hofig et al., “Poloxamer synperonic F108 improves cellular transduction with lentiviral vectors,” J Gene Med, Aug. 2012, vol. 14, No. 8, pp. 549-560; abstract, p. 551, col. 1, para 4 to col. 2, para 1, p. 552, Table 1, …
[cited by applicant]
Albert, et al., “Site-specific integration of DNA into wild-type and mutant lox sites placed in the plant genome.” Plant J. (1995); 7(4): 649-659.
[cited by applicant]
Anastasov et al., “Optimized Lentiviral Transduction Protocols by Use of a Poloxamer Enhancer, Spinoculation, and scFv-Antibody Fusions to VSV-G,” Methods Mol Biol. 2016;1448:49-61.
[cited by applicant]
Arumugam, et al., “Genetic therapy for beta-thalassemia: from the bench to the bedside”, Hematology Am Soc Hematol Educ Program. (2010); 445-50.
[cited by applicant]
Beard, B.C. et al., “Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates”, J Clin Invest. (2010), 120(7): 2345-2354.
[cited by applicant]
Bell, et al., “The protein CTCF is required for the enhancer blocking activity of vertebrate insulators”, Cell. (1999); 98(3): 387-96.
[cited by applicant]
Belteki, et al., “Site-specific cassette exchange and germline transmission with mouse ES cells expressing φC31 integrase.” Nature Biotechnology (2003); 21: 321-324.
[cited by applicant]
Bethke et al., “Segmental genomic replacement by Cre-mediated recombination: genotoxic stress activation of the p53 promoter in single-copy transformants.” Nucleic Acids Research (1997); 25(14): 2828-2834.
[cited by applicant]
Bird, Robert E., et al. “Single-chain antigen-binding proteins.” Science (1988); 242.4877: 423-426.
[cited by applicant]
Burgess-Beusse, B. et al., “The insulation of genes from external enhancers and silencing chromatin”, Proc Natl Acad Sci USA (2002), 99(Suppl 4):16433-16437.
[cited by applicant]
Carell, Thomas, et al. “A novel procedure for the synthesis of libraries containing small organic molecules.” Angewandte Chemie International Edition in English (1994); 33.20: 2059-2061.
[cited by applicant]
Carell, Thomas, et al. “A Solution-Phase Screening Procedure for the Isolation of Active Compounds from a Library of Molecules.” Angewandte Chemie International Edition in English (1994); 33.20: 2061-2064.
[cited by applicant]
Cartier, N., et al., “Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy.” Science (2009); 326(5954): 818-823.
[cited by applicant]
Cavazzana-Calvo, M. et al., “Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia”, Nature (2010), 467(7313): 318-322.
[cited by applicant]
Cavrois, et al., “A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes.” Nat Biotechnol. (2002); 20 (11): 1151-1154. Epub Sep. 30, 2002.
[cited by applicant]
Chang, A.H., et al., “Erythroid-specific Human Factor IX Delivery From In Vivo Selected Hematopoietic Stem Cells Following Nonmyeloablative Conditioning in Hemophilia B Mice”, Molecular Therapy (2008), 16(10): 1745-1752.
[cited by applicant]
Chaudhary, Vuay K., et al. “A rapid method of cloning functional variable-region antibody genes in
[cited by applicant]
Cho, Charles, et al. “An Unnatural Biopolymer,” Science, vol. 261, Sep. 3, 1993, 1303-1304.
[cited by applicant]
Chung, et al., “A 5′ element of the chicken beta-globin domain serves as an insulator in human erythroid cells and protects against position effect in
[cited by applicant]
Chung, et al., “Characterization of the chicken beta-globin insulator”, Proc Natl Acad Sci U S A. (1997); 94(2): 575-80.
[cited by applicant]
Clever, J. et al., “RNA Secondary Structure and Binding Sites for gag Gene Products in the 59 Packaging Signal of Human Immunodeficiency Virus Type 1”, J. of Virology (1995), 69(4): 2101-2109.
[cited by applicant]
Cooper, Laurence JN, et al. “T-cell clones can be rendered specific for CD19: Toward the selective augmentation of the graft-versus-B-lineage leukemia effect.” Blood (2003); 101.4: 1637-1644.
[cited by applicant]
Cornetta, K. et al., “A pilot study of dose-intensified procarbazine, CCNU, vincristine for poor prognosis brain tumors utilizing fibronectin-assisted, retroviral-mediated modification of CD34+ peripheral blood cells wi…
[cited by applicant]
Cullen et al., “Regulatory pathways governing HIV-1 replication”, Cell (1989), 58: 423-426.
[cited by applicant]
Cullen, B.R., “Human immunodeficiency virus as a prototypic complex retrovirus”, Journal of Virology (1991), 65(3): 1053-1056.
[cited by applicant]
Dayhoff, M. et al., “A model of evolutionary change in proteins. In: Atlas of Protein Sequence and Structure”, M.O. Dayhoff, (1978) ed., pp. 345-358. National Biomedical Research Foundation, Washington, DC.
[cited by applicant]
Desjarlais et al. “Use of a zinc-finger consensus sequence framework and specificity rules to design specific DNA binding proteins.” Proceedings of the National Academy of Sciences (1993); 90.6:2256-2260.
[cited by applicant]
DeWitt, S. Hobbs, et al. “Diversomers: An approach to nonpeptide, nonoligomeric chemical diversity.” Proceedings of the National Academy of Sciences USA (1993); 90.15: 6909-6913.
[cited by applicant]
Dull et al., “A third-generation lentivirus vector with a conditional packaging system”, Journal of Virology (1998), 72(11): 8463-8671.
[cited by applicant]
Dunbar, C.E. et al., “Retroviral Transfer of the Glucocerebrosidase Gene into CD34+ Cells from Patients with Gaucher Disease: In Vivo Detection of Transduced Cells without Myeloablation”, Human Gene Therapy (1998), 9(17…
[cited by applicant]
Finotti, et al., “Recent trends in the gene therapy of β-thalassemia”, J Blood Med. (2015); 6: 69-85.
[cited by applicant]
Gallop, Mark A., et al. “Applications of combinatorial technologies to drug discovery. 1. Background and peptide combinatorial libraries.” Journal of Medicinal Chemistry (1994); 37.9: 1233-1251.
[cited by applicant]
Ginn, et al., “Gene therapy clinical trials worldwide to 2012—an update.” The Journal of Gene Medicine (2013); 15 (2): 65-77.
[cited by applicant]
Groth, et al., “A phage integrase directs efficient site-specific integration in human cells.” PNAS (2000); 97(11): 5995-6000.
[cited by applicant]
Hacein-Bey-Abina, S., et al., “LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1.” Science (2003); 302 (5644): 415-419.
[cited by applicant]
Hoban et al., “Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease”, Blood. (2016); 127(7): 839-848.
[cited by applicant]
Hoess, et al., “The role of the IoxP spacer region in P1 site-specific recombination,” Nucleic Acids Res, 14 (1986), pp. 2287-2300.
[cited by applicant]
Höfig et al., “Poloxamer synperonic F108 improves cellular transduction with lentiviral vectors,”. J Gene Med. Aug. 2012; 14(8):549-60.
[cited by applicant]
Huang and Yen, “Role of the hepatitis B virus posttranscriptional regulatory element in export of intronless transcripts”, Mol. Cell. Biol. (1995), 15(7): 3864-3869.
[cited by applicant]
Imren, S. et al., “Permanent and panerythroid correction of murine β thalassemia by multiple lentiviral integration in hematopoietic stem cells”, Proc Natl Acad Sci U S A (2002), 99(22): 14380-14385.
[cited by applicant]
Irion, S. et al., “Identification and targeting of the ROSA26 locus in human embryonic stem cells”, Nat Biotechnol. (2007); 25(12):1477-1482.
[cited by applicant]
Jackson, et al., “Internal initiation of translation in eukaryotes: the picornavirus paradigm and beyond”, RNA. (1995); 1(10): 985-1000.
[cited by applicant]
Jackson, et al., “The novel mechanism of initiation of picornavirus RNA translation”, Trends Biochem Sci. (1990); 15(12): 477-483.
[cited by applicant]
Kim, Yang-Gyun, et al., “Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain.” Proceedings of the National Academy of Sciences (1996); 93.3: 1156-1160.
[cited by applicant]
Kozak, M., “An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs”,
[cited by applicant]
Kozak, M., “Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes”,
[cited by applicant]
Kunkel, et al.“Rapid and efficient site-specific mutagenesis without phenotypic selection”, Methods in Enzymol. (1987); 154: 367-382.
[cited by applicant]
Kunkel, TA. “Rapid and efficient site-specific mutagenesis without phenotypic selection”, Proc Natl Acad Sci U S A. (1985); 82(2): 488-492.
[cited by applicant]
Kutner et al., “Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors”, Nature Protocols (2009); 4: 495-505.
[cited by applicant]
Kutner, et al., “Simplified production andconcentration of HIV-1-based lentiviral vectors using HYPERFlask vessels and anion exchange membrane chromatography”, BMC Biotechnol. (2009); 9:10. p. 1-7.
[cited by applicant]
Landau and Littman. “Packaging system for rapid production of murine leukemia virus vectors with variable tropism.” Journal of Virology (1992); 66.8: 5110-5113.
[cited by applicant]
Landy, A. “Mechanistic and structural complexity in the site-specific recombination pathways of Int and FLP”, Curr Opin Genet Dev. (1993); 3(5): 699-707.
[cited by applicant]
Langer, et al., “A genetic screen identifies novel non-compatible IoxP sites,” Nucleic Acids Res, 30 (2002), pp. 3067-3077.
[cited by applicant]
Lee et al., “Role of nucleotide sequences of IoxP spacer region in Cre-mediated recombination.” Gene (1998); 216 (1): 55-65.
[cited by applicant]
Levasseur, D.N. et al., “Correction of a mouse model of sickle cell disease: lentiviral/antisickling beta-globin gene transduction of unmobilized, purified hematopoietic stem cells”, Blood (2003), 102(13): 4312-4319.
[cited by applicant]
Liu and Mertz, “HnRNP L binds a cis-acting RNA sequence element that enables intron-dependent gene expression”, Genes & Dev. (1995), 9: 1766-1780.
[cited by applicant]
Liu, Qiang, et al. “Design of polydactyl zinc-finger proteins for unique addressing within complex genomes.” Proceedings of the National Academy of Sciences (1997); 94.11: 5525-5530.
[cited by applicant]
Lowy, et al., “Isolation of transforming DNA: cloning the hamster aprt gene”, Cell. (1980); 22(3): 817-823.
[cited by applicant]
MaGuire, A.M. et al., “Safety and efficacy of gene transfer for Leber's congenital amaurosis”, N Engl J Med. (2008), 358(21): 2240-2248.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2017/017372, dated Apr. 27, 2017, 13 pages.
[cited by applicant]
Bertrand et al., “Induction of a Common Pathway of Apoptosis by Staurosporine,” Experimental Cell Research, vol. 211, Issue 2, Apr. 1994, pp. 314-321.
[cited by applicant]
Buschke et al., “Cell death, non-invasively assessed by intrinsic fluorescence intensity of NADH, is a predictive indicator of functional differentiation of embryonic stem cells,” Biol Cell. Jun. 2012; 104(6): 352-364.
[cited by applicant]
Extended European Search Report issued in European Application No. 17750819.9 dated Aug. 27, 2019, 8 pages.
[cited by applicant]
Hughes et al., “Regulation of pluripotent cell differentiation by a small molecule, taurosporine,” Differentiation, 87, Feb. 28, 2014, pp. 101-110.
[cited by applicant]
Lai et al., “T and B lymphocyte differentiation from hematopoietic stem cell,” Seminars in Immunology, vol. 20, No. 4, Aug. 1, 2008, 6 pages.
[cited by applicant]
Rodriguez et al., “Induction of Alkalinization in Cultured Renal Cells (MDCK Line) by Prostaglandin E2,” Prostaglandins, vol. 49, No. 2, Feb. 1, 1995, 13 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2017/017351, dated Apr. 28, 2017, 11 pages.
[cited by applicant]
Liu et al. “Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line,” J Biol Chem, Oct. 24, 2002 (Oct. 24, 2002), vol. 277, No. 51, pp. 50081-…
[cited by applicant]
Yoder et al. “HIV envelope-CXCR4 signaling activates cofilin to overcome cortical actin restriction in resting CD4 T cells,” Cell, Sep. 5, 2008 (Sep. 5, 2008), vol. 134, No. 5, pp. 782-792. entire document.
[cited by applicant]
Zhao, Xiao-yu, et al. “Enhancing Lentiviral Vector Transduction Efficiency for Facilitating Gene Therapy.”
[cited by applicant]
Notice of Allowance and Fee(s) Due issued in Application No. U.S. Appl. No. 16/076,950, dated Jan. 3, 2022.
[cited by applicant]
Notice of Allowability issued in Application No. U.S. Appl. No. 16/076,950, dated Mar. 10, 2022.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/125,930 dated Jul. 25, 2023.
[cited by applicant]
Corrected Notice of Allowability for U.S. Appl. No. 17/125,930 dated Aug. 17, 2023.
[cited by applicant]
The European Agency for the Evaluation of Medicinal Products (Feb. 1997, Committee for Proprietary Medicinal Products, pp. 1-6).
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/125,930, dated Jan. 6, 2023.
[cited by applicant]
Xinchen Sun, “Clinical Molecular Oncology,” Southeast University Press (2008).
[cited by applicant]
Case, et al. “Stable transduction of quiescent CD34 + CD38 human hematopoietic cells by HIV-1- based lentiviral vectors,” Proceedings of the National Academy of Sciences, 96.6:2988-2993, (1999).
[cited by applicant]
De Waart, et al., “Multidrug resistance associated protein 2 mediates transport of prostaglandin E2,” Liver International, 26.3:362-368, (2006).
[cited by applicant]
Gao, et al., “Changes of T Cell Subsets in the Peripheral Blood of Mice after Mobilization of Hematopoietic Stem Cells by G-CSF and GM-CSF,” Acta Academiae Medicine Xuzhou, Jul. 2007, DD. 1-2, vol. 27, No., 7. One page …
[cited by applicant]
Giry-Laterriere, et al., Chapter 8 pp. 183-209; Lentiviral Vectors. In: Merten OW., Al-Rubeai M. (eds) Viral Vectors for Gene Therapy. Methods in Molecular Biology (Methods and Protocols), vol. 737. Humana Press; ISBN: …
[cited by applicant]
Hayakawa, et al., “Transient in Vivo-Globin Production After Lentiviral Gene Transfer to Hematopoietic Stem Cells in the Nonhuman Primate,”
[cited by applicant]
Heffner, et al., “Prostaglandin E2 Increases Lentiviral Vector Transduction Efficiency of Adult Human Hematopoietic Stem and Progenitor Cells,” Mol Ther, 89926, 1:320-328, (2018).
[cited by applicant]
Hoggart, “Eicosanoid Regulation of Hematopoietic, Stem, and ProgenPubitor Cell Function,” Permanent link: http://hdl.handle.net/1805/2206 date: Jul. 21, 2010.
[cited by applicant]
Li, et al., “Optimal promoter usage for lentiviral vector-mediated transduction of cultured central nervous system cells,” J. Neurosci Methods, 189(1):56-64, (May 30, 2010).
[cited by applicant]
Liu, et al., “Identification of parameters required for efficient lentiviral, vector transduction and engraftment of human cordblood CD34+ NOD/SCID-re-populating cells,” Exp. Hematrol. 35:947-956, (2008).
[cited by applicant]
Malik, et al., “Successful Correction of the Human Cooley's Anemia—Thalassemia Major Phenotype Using a Lentiviral Vector Flanked by the Chicken Hypersensitive Site 4 Chromatin Insulator,” Annals of the New York Academy …
[cited by applicant]
May, et al., “Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human beta-globin,”
[cited by applicant]
McLeod, et al., “Identification of the crossover site during FLP-mediated recombination in the Saccharomyces cerevisiae plasmid 2 microns circle,”
[cited by applicant]
Miller, “Human gene therapy comes of age,”
[cited by applicant]
Milsom, et al., “Reciprocal relationship between 06-Methylguanine-DNA methyltransferase P140K expression level and chemoprotection of hematopoietic stem cells,”
[cited by applicant]
Naldini, et al., “Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector,”
[cited by applicant]
Naldini, et al., “In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector,”
[cited by applicant]
Naldini, “Gene therapy returns to centre stage,”
[cited by applicant]
Naldini, “Lentiviruses as gene transfer agents for delivery to non-dividing cells,”
[cited by applicant]
Nguyen, et al., “Highly efficient lentiviral vector-medicated transduction of nondividing, fully reimplantable primary hepatocytes, ” Molecular therapy 6.2:199-209, (2002).
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 15/997,643, dated May 9, 2019.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/665,892, dated Apr. 29, 2020.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 15/997,643, dated Sep. 24, 2019.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/665,892, dated Oct. 8, 2020.
[cited by applicant]
Notice of appeal of opposition decision of Patent No. EP 2760994, dated Jan. 16, 2020.
[cited by applicant]
Notice of opposition to a European Patent in Patent No. EP 3269802, on behalf of HGF Limited, dated Jul. 21, 2020.
[cited by applicant]
Notice of opposition to a European Patent in Patent No. EP 3269802, on behalf of Script IP Limited, dated Jul. 23, 2020.
[cited by applicant]
Patel, et al., “Impact of chimeric immune receptor extracellular protein domains on T cell function,”
[cited by applicant]
Pawliuk, et al. “Correction of sickle cell disease in transgenic mouse models by gene therapy.”
[cited by applicant]
Pestina, et al., “Correction of murine sickle cell disease using gamma-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin,”
[cited by applicant]
Piacibello, et al., “Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID mice,”
[cited by applicant]
Pomerantz, et al. “Structure-based design of transcription factors,”
[cited by applicant]
PubChem entry for Thromoxane B2 (from printed 2018 https://pubchem.ncbi.nlm.nih.gov/compound/thromboxane_B2) printed 2018.
[cited by applicant]
Reddy, et al., “Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Reduces Acute Graft-Versus-Host Disease and Preserves Graft-Versus-Leukemia Effect,”
[cited by applicant]
Robertson, et al., “Thromboxane A2 in vasotonic angina pectoris: evidence from direct measurements and inhibitor trials,”
[cited by applicant]
Santoni De Sio et al., “Short-term culture of human CD34+ cells for lentiviral gene transfer,”
[cited by applicant]
Sauer, “Site-specific recombination: developments and applications,”
[cited by applicant]
Schlake, et al., “Use of mutated FLP recognition target (FRT) sites for the exchange of expression cassettes at defined chromosomal loci,”
[cited by applicant]
Scott, et al., “Gene therapy's out-of-body experience,”
[cited by applicant]
Senecoff, et al., “DNA Recognition by the FLP Recombinase of the Yeast 2 μ Plasmid,”
[cited by applicant]
Sibbald, et al., “Doctors asked to take pledge to shun drug company freebies,”
[cited by applicant]
Sirin, et al., “Regulating gene expression using self-inactivating lentiviral vectors containing the mifepristone-inducible system,”
[cited by applicant]
Soneoka, et al. “A transient three-plasmid expression system for the production of high titer retroviral vectors,”
[cited by applicant]
Structural Similarity of Prostaglandins.
[cited by applicant]
Technical Resource document detailing formulation of Gibco TM—IMDM (Catalogue No. 12440-ThermoFisher Scientific) / https://www.thermofisher.com/uk/en/home/technical-resources/media-formulations.76 html.
[cited by applicant]
Tesio, et al., “Substained Long-Term Engraftment and Transgene Expression of Peripheral Blood CD34+ Cells Transduced with Third-Generation Lentiviral Vectors,”
[cited by applicant]
Thyagarajan, et al., “Site-specific genomic integration in mammalian cells mediated by phage @C31 integrase,”
[cited by applicant]
Uchida, et al. “Optimal conditions for lentiviral transduction of engrafting human CD34+ cells.”
[cited by applicant]
Uchida, et al., “Development of a human immunodeficiency virus type 1-based lentiviral vector that allows efficient transduction of both human and rhesus blood cells,”
[cited by applicant]
Ueno, et al., “Possible pathogenesis of acquired immune deficiency syndrome in homosexual males: an unexpected action of seminal prostaglandin E2 on AIDS-virus infection,”
[cited by applicant]
White, et al., “Comparison of the glycosyl-phosphatidylinositol cleavage/attachment site between mammalian cells and parasitic protozoa,”
[cited by applicant]
Wigler, et al., “Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells,”
[cited by applicant]
Xinhua, “X-Linked Adrenoleukodystrophy,”
[cited by applicant]
Zennou, et al., “HIV-1 genome nuclear import is mediated by a central DNA flap,”
[cited by applicant]
Zhan, et al., “Insulator: from chromatin domain boundary to gene regulation,”
[cited by applicant]
Zhou, et al. “Quantitative shearing linear amplification polymerase chain reaction: an improved method for quantifying lentiviral vector insertion sites in transplanted hematopoietic cell systems,”
[cited by applicant]
Zuckermann, et al. “Discovery of nanomolar ligands for 7-transmembrane G-protein-coupled receptors from a diverse N-(substituted) glycine peptoid library,”
[cited by applicant]
Zufferey, et al., “Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo,”
[cited by applicant]
Zufferey, et al., “Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors,”
[cited by applicant]